Loading…
Zai Lab Limited is projected to rise to $22.05 by 2027, a +21% move from its current price of $18.21. ZLAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $17.86 | $18.22 | $18.59 | +0.06% |
| Aug 2 | $17.72 | $18.23 | $18.76 | +0.11% |
| Aug 3 | $17.62 | $18.24 | $18.89 | +0.17% |
| Aug 4 | $17.53 | $18.25 | $19.00 | +0.22% |
| Aug 5 | $17.46 | $18.26 | $19.10 | +0.28% |
| Aug 6 | $17.39 | $18.27 | $19.19 | +0.33% |
| Aug 7 | $17.33 | $18.28 | $19.28 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.33 | $18.28 | $19.28 | +0.39% |
| Week 2 | $17.02 | $18.35 | $19.79 | +0.78% |
| Week 3 | $16.80 | $18.42 | $20.20 | +1.17% |
| Week 4 | $16.63 | $18.50 | $20.57 | +1.57% |
| Week 5 | $16.48 | $18.57 | $20.92 | +1.96% |
| Week 6 | $16.36 | $18.64 | $21.24 | +2.36% |
| Week 7 | $16.25 | $18.71 | $21.54 | +2.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zai Lab Limited is a biopharmaceutical company focused on discovering, developing, and commercializing products that address medical conditions in oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.
The company was incorporated in 2013 and is based in Pudong, China.
This positioning places it among mid-cap healthcare peers in the global biopharma space. The near-term price outlook is nuanced by technical signals, while long-range forecasts suggest a bullish trajectory driven by expanding revenue opportunities and product approvals across its oncology and immune-oncology portfolio. The stock operates in a high-volatility environment, reflecting the inherent uncertainty of biotech equities.
A major floor 11.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 13.9% above — a clean break opens room to run.
A major ceiling 38.7% above — clearing it would confirm fresh momentum.
Key ZLAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZLAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.60 | Sell | $18.66 | Sell |
| MA 10 | $19.44 | Sell | $19.08 | Sell |
| MA 20 | $19.61 | Sell | $19.24 | Sell |
| MA 50 | $18.62 | Sell | $19.19 | Sell |
| MA 100 | $19.50 | Sell | $19.56 | Sell |
| MA 200 | $20.00 | Sell | $21.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.22 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -140.29 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.27 | Sell |
| ROC (12) | -5.65 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 16.39 | Buy |
| Momentum (10) | -2.54 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 17.94 | Buy |
| ADX (14) | 17.38 | Neutral |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is bearish. RSI14 stands at 40, and the stock trades around the moving averages, with the SMA50 at $18.63 and the SMA200 at $20.06. Immediate support is indicated at $17.73 and resistance at $20.75.
The 30-day trading range spans from $15.97 to $20.99, underscoring near-term volatility and downside risk that could test the support level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.30 | $18.21 | $24.49 | 0% | Neutral | |
| $18.01 | $22.05 | $28.28 | +21% | Bullish | |
| $17.93 | $22.41 | $29.57 | +23% | Bullish | |
| $20.02 | $25.44 | $34.34 | +40% | Bullish | |
| $20.84 | $26.87 | $36.96 | +48% | Bullish | |
| $22.51 | $29.41 | $41.14 | +62% | Bullish | |
| $27.24 | $36.02 | $51.15 | +98% | Bullish | |
| $29.27 | $39.15 | $56.36 | +115% | Bullish | |
| $31.75 | $42.92 | $62.57 | +136% | Bullish | |
| $33.71 | $46.04 | $67.91 | +153% | Bullish | |
| $48.50 | $69.34 | $107.46 | +281% | Bullish | |
| $80.79 | $124.65 | $207.81 | +585% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.30 | $18.21 | $21.21 | +0.00% |
| August 2026 | $16.01 | $18.69 | $22.25 | +2.65% |
| September 2026 | $16.31 | $19.16 | $23.03 | +2.48% |
| October 2026 | $16.18 | $19.10 | $23.14 | -0.29% |
| November 2026 | $16.29 | $19.30 | $23.54 | +1.06% |
| December 2026 | $16.79 | $19.97 | $24.49 | +3.44% |
Click any year to see its month-by-month ZLAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ZLAB could reach as high as $24.49, with a base case around $18.21 and support toward $16.30 — roughly 0% from $18.21. Price action looks broadly range-bound.
Expect ZLAB to range from $18.01 to $28.28 through 2027. The $22.05 average target implies a +21% move from current prices. That is up +21% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ZLAB price prediction for 2028 points to an average of $22.41 (low $17.93, high $29.57) — a potential gain of +23% on today's $18.21. Momentum favours further upside here.
In 2029, ZLAB is projected to trade between $20.02 and $34.34, averaging $25.44 — a potential gain of +40% from today's $18.21. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Zai Lab Limited's 2030 outlook centres on $26.87, within a $20.84 to $36.96 range. That is up +6% on the projected 2029 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2031, ZLAB could reach as high as $41.14, with a base case around $29.41 and support toward $22.51 — roughly +62% from $18.21. Buyers look set to stay in control over this stretch.
Expect ZLAB to range from $27.24 to $51.15 through 2032. The $36.02 average target implies a +98% move from current prices. That is up +22% on the projected 2031 average. Momentum favours further upside here.
The ZLAB price prediction for 2033 points to an average of $39.15 (low $29.27, high $56.36) — a potential gain of +115% on today's $18.21. Buyers look set to stay in control over this stretch.
In 2034, ZLAB is projected to trade between $31.75 and $62.57, averaging $42.92 — a potential gain of +136% from today's $18.21. That is up +10% on the projected 2033 average. Momentum favours further upside here.
Zai Lab Limited's 2035 outlook centres on $46.04, within a $33.71 to $67.91 range. That is up +7% on the projected 2034 average. That marks a +153% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ZLAB could reach as high as $107.46, with a base case around $69.34 and support toward $48.50 — roughly +281% from $18.21. Momentum favours further upside here.
Expect ZLAB to range from $80.79 to $207.81 through 2050. The $124.65 average target implies a +585% move from current prices. That is up +80% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZLAB today (≈ 54.914882 ZLAB) could be worth
$6,845.18
+$5,845.18 (+585%) by 2050 · US Dollar
Based on the average projected ZLAB price of $124.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZLABwould be worth at today's price.
$1,000 invested in ZLAB on Jul 30, 2025 (≈ 25.926886 ZLAB) would be worth
$472.13
-$527.87 (-52.8%) today · 0.47× · US Dollar
Based on a ZLAB entry price of $38.57 vs. today's $18.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.68 | $925.3 | -7.5% |
| 1 month ago | $19 | $958.42 | -4.2% |
| 3 months ago | $21.54 | $845.4 | -15.5% |
| 6 months ago | $16.6 | $1,096.99 | +9.7% |
| 1 year ago | $38.57 | $472.13 | -52.8% |
| All time (5.0y) ago | $144.93 | $125.65 | -87.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZLAB forecast.
Our base-case forecast reaches $36.00 around 2032.
Implied market cap at $36.00: $4.07B
The multi-year forecast shows a bullish trajectory across the horizon. In 2026, the avg price is $18.31 with a min of $16.30, a max of $24.67 and ROI of 0% (neutral sentiment). By 2027, the avg rises to $22.09 with a min of $18.00, a max of $28.41 and ROI of 20.6% (bullish).
In 2028, avg $22.40, min $17.88, max $29.68, ROI 22.4% (bullish), and in 2029, avg $25.39, min $19.91, max $34.42, ROI 38.6% (bullish). By 2030, avg $26.71, min $20.64, max $36.93, ROI 45.9% (bullish). The forecast extends to 2031 ($29.17 avg, ROI 59.3%), 2032 ($35.66 avg, ROI 94.8%), 2033 ($38.70 avg, ROI 111.4%), 2034 ($42.42 avg, ROI 131.7%), and 2035 ($45.45 avg, ROI 148.2%) with bullish sentiment.
Looking further ahead, 2040 shows avg $68.08, min $47.27, max $106.31 and ROI 271.8% (bullish), while 2050 projects avg $121.87, min $78.17, max $205.04 and ROI 565.6% (bullish). These figures illustrate a sustained upward trajectory in the long run, but investors should treat them as estimates, not guarantees, and remain aware of inherent biotech risks.
Tap a question to reveal the answer.
2030: avg $26.71, min $20.64, max $36.93; ROI 45.9%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with 2027 avg $22.09 (ROI 20.6%), 2031 ROI 59.3%, 2035 ROI 148.2%, 2040 ROI 271.8%, and 2050 ROI 565.6%.
Yes, the max forecast reaches $106.31 in 2040 (min $47.27, max $106.31) and $205.04 in 2050, indicating potential strength in the max scenario.
Current price: $18.31; Market cap: $2.07B.
Bearish sentiment with RSI 40. SMA50 is $18.63 and SMA200 is $20.06. 30-day range: $15.97–$20.99. Support at $17.73 and resistance at $20.75.
Zai Lab Limited Community Discussion
0Share your Zai Lab Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.